Asset profile
Talquetamab
Multispecific antibody
Evidence outlook
Accelerated approval: Multiple Myeloma (label: relapsed/refractory multiple myeloma after >= 4 prior lines of therapy)
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Talquetamab: this drug | Approved | Multispecific antibody | GPRC5D x CD3 | ||
| QLS32015 | Phase 3 | Multispecific antibody | GPRC5D x CD3 | ||
| Forimtamig | Phase 1/2 | Multispecific antibody | GPRC5D x CD3 | ||
| LBL-034 | Phase 1/2 | — | GPRC5D x CD3 | ||
| TQB2029 | Phase 1 | Multispecific antibody | GPRC5D x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(28 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (13)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (4)
What to watch
What to watch
What to watch
What to watch
August 2027 (2)
October 2027 (1)
What to watch
2028 (3)
April 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
April 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (4)
March 2030 (1)
What to watch
April 2030 (1)
What to watch
May 2030 (1)
What to watch
September 2030 (1)
What to watch
2031 (2)
2033 (1)
June 2033 (1)
What to watch
2036 (1)
December 2036 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.